Navigation Links
Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
Date:10/13/2008

Expansion of Genomic DNA from Multiple Cancer Populations Facilitates

Disease Studies

ANN ARBOR, Mich., Oct. 13 /PRNewswire/ -- Rubicon Genomics, Inc. today announced an agreement with SAIC-Frederick to amplify DNA samples for The Cancer Atlas Genome Project.

Rubicon Genomics was selected to amplify and standardize total genomic DNA from 3,000 tissue and blood samples from cancer patients. The Rubicon GenomePlex(TM) Whole Genome Amplification technology was judged best to amplify clinical DNA samples to the constant concentration and quality necessary for reproducible and accurate analysis using microarrays and PCR. The amplified DNA libraries will be deposited into the International Genomics Consortium Biospecimen Research Core as a renewable resource to be shared among international researchers to completely characterize the genomes of patients with three types of cancer. Their studies will help understand the causes of cancer, as well as how to detect and treat the diseases.

"This agreement is an important technical validation for GenomePlex," said Dr. John Langmore, vice-president of commercial development for Rubicon. "IGC-BRC collaborators were able to show that pre-amplification of patient DNA can increase the sensitivity, reproducibility and robustness of analysis of patient samples using major analytical instruments."

Rubicon provides custom GenomePlex services for major pharmaceutical, diagnostic and institutional customers in order to increase the clinical performance of genetic analysis instruments. GenomePlex kits are also available from Rubicon for diagnostic applications. GenomePlex not only makes analysis of routine frozen tissue more reproducible, but enables difficult clinical samples such as single cells, plasma, serum and formalin-fixed tissue to be analyzed by PCR, microarrays and next-gen sequencing. Furthermore, GenomePlex allows investigators and clinicians to test for multiple analytes from a single small sample, producing more information from clinical samples.

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, MI, is a pre-analytical platform company that has developed and commercialized reagents and kits to increase the analytical and clinical performances of DNA and RNA analysis platforms including Q-PCR, microarrays, and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and MethylPlex(TM) products achieve unbiased amplification and standardization of total DNA, total RNA, and methylated DNA. By producing highly pure DNA of uniform concentration and molecular weight these products increase the sensitivity, specificity, and reproducibility of conventional instrumentation in research and diagnostic applications, including analysis of single cells, formalin-fixed tissue and plasma. Rubicon sells GenomePlex and TransPlex services to the research market, as well as licenses and kits to the clinical markets, including pre-implantation and prenatal testing, and diagnostic manufacturing. GenomePlex and TransPlex kits are sold to the research-only market by Sigma-Aldrich. In addition, Rubicon partners with diagnostic companies, using its pre-analytical MethylPlex platform to discover and validate new DNA methylation biomarkers, and to co-develop cancer diagnostic tests. For more information contact John Langmore, VP Commercial Development, at langmore@rubicongenomics.com or (734) 368-1705.

About IGC

The International Genomics Consortium (IGC) is a non-profit medical research foundation established to expand upon the discoveries of the Human Genome Project and other systematic sequencing efforts by combining world- class genomic research, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. IGC serves numerous common, unmet needs including: the standardization of the collection of properly consented tissues of interest, the molecular characterization of these tissues, and standardization in the representation of these results. IGC facilitates the transition of genomic discoveries to improve patient care and increase the speed in which new diagnostic, prognostic and predictive testing, and new drug and treatment regimens are developed. Founding support for IGC was provided by the City of Phoenix and from Maricopa County.

Contact: John Langmore

VP Commercial Development

(734) 368-1705

langmore@rubicongenomics.com


'/>"/>
SOURCE Rubicon Genomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. Fralex provides update on timing of interim analysis results
4. Vanda Pharmaceuticals Provides Update on Iloperidone
5. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
6. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
7. New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
8. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
9. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
10. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
11. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):